Clinical Cancer Research, Vol 4, Issue 5 1215-1220, Copyright © 1998 by American Association for Cancer Research

ARTICLES

Quantitative [F-18]fluorodeoxyglucose positron emission tomography in pretreatment and grading of sarcoma

JF Eary, EU Conrad, JD Bruckner, A Folpe, KJ Hunt, DA Mankoff and AT Howlett
University of Washington Medical Center, Seattle 98195-6113, USA.

The purpose of this study was to determine the relationship between sarcoma tumor grade and the quantitative tumor metabolism value for [F-18]fluorodeoxyglucose (FDG) determined by positron emission tomography (PET) imaging. Seventy patients with bone or soft-tissue sarcomas underwent PET scanning with quantitative determination of tumor FDG metabolic rate (MRFDG) before treatment. MRFDG (micromol/g/min) for each tumor was compared with National Cancer Institute tumor grade, S-phase percentage, and percentage of aneuploidy of the tumor population. The pretreatment quantitative determination of tumor MRFDG by PET correlates strongly with tumor grade but not with the other selected histopathological tumor correlates. In addition, overlap of MRFDG PET values with tumor grade suggests that PET, an objective tumor measurement, may provide an alternative means of assessing tumor biological potential or may have the potential to overcome some of the limitations of traditional pathological evaluation. FDG PET can uniquely provide a metabolic profile of a diverse group of sarcomas noninvasively and provide clinically relevant tumor biological information.

This article has been cited by other articles:

				A. K. Buck, K. Herrmann, C. M. z. Buschenfelde, M. E. Juweid, M. Bischoff, G. Glatting, G. Weirich, P. Moller, H.-J. Wester, K. Scheidhauer, et al. Imaging Bone and Soft Tissue Tumors with the Proliferation Marker [18F]Fluorodeoxythymidine Clin. Cancer Res., May 15, 2008; 14(10): 2970 - 2977. [Abstract] [Full Text] [PDF]

				G. C. Toner and R. J. Hicks PET for Sarcomas Other Than Gastrointestinal Stromal Tumors Oncologist, April 1, 2008; 13(suppl_2): 22 - 26. [Abstract] [Full Text] [PDF]

				U. Tateishi, U. Yamaguchi, K. Seki, T. Terauchi, Y. Arai, and E. E. Kim Bone and Soft-Tissue Sarcoma: Preoperative Staging with Fluorine 18 Fluorodeoxyglucose PET/CT and Conventional Imaging Radiology, December 1, 2007; 245(3): 839 - 847. [Abstract] [Full Text] [PDF]

				R. A. Huddart, M. J. O'Doherty, A. Padhani, G. J.S. Rustin, G. M. Mead, J. K. Joffe, P. Vasey, S. J. Harland, J. Logue, G. Daugaard, et al. 18Fluorodeoxyglucose Positron Emission Tomography in the Prediction of Relapse in Patients With High-Risk, Clinical Stage I Nonseminomatous Germ Cell Tumors: Preliminary Report of MRC Trial TE22 The NCRI Testis Tumour Clinical Study Group J. Clin. Oncol., July 20, 2007; 25(21): 3090 - 3095. [Abstract] [Full Text] [PDF]

				J. S. Weisstein, R. E. Goldsby, and R. J. O'Donnell Oncologic Approaches to Pediatric Limb Preservation J. Am. Acad. Ortho. Surg., December 1, 2005; 13(8): 544 - 554. [Abstract] [Full Text] [PDF]

				D. S. Hawkins, S. M. Schuetze, J. E. Butrynski, J. G. Rajendran, C. B. Vernon, E. U. Conrad III, and J. F. Eary [18F]Fluorodeoxyglucose Positron Emission Tomography Predicts Outcome for Ewing Sarcoma Family of Tumors J. Clin. Oncol., December 1, 2005; 23(34): 8828 - 8834. [Abstract] [Full Text] [PDF]

				G. J. Kelloff, J. M. Hoffman, B. Johnson, H. I. Scher, B. A. Siegel, E. Y. Cheng, B. D. Cheson, J. O'Shaughnessy, K. Z. Guyton, D. A. Mankoff, et al. Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development Clin. Cancer Res., April 15, 2005; 11(8): 2785 - 2808. [Abstract] [Full Text] [PDF]

				E. U. Conrad III, H. D. Morgan, C. Vernon, S. M. Schuetze, and J. F. Eary Fluorodeoxyglucose Positron Emission Tomography Scanning: Basic Principles and Imaging of Adult Soft-Tissue Sarcomas J. Bone Joint Surg. Am., December 1, 2004; 86(suppl_2): 98 - 104. [Full Text] [PDF]

				S. Beaulieu, B. Rubin, D. Djang, E. Conrad, E. Turcotte, and J. F. Eary Positron Emission Tomography of Schwannomas: Emphasizing Its Potential in Preoperative Planning Am. J. Roentgenol., April 1, 2004; 182(4): 971 - 974. [Abstract] [Full Text] [PDF]

				D. C. P. Cobben, P. H. Elsinga, A. J. H. Suurmeijer, W. Vaalburg, B. Maas, P. L. Jager, and H. J. Hoekstra Detection and Grading of Soft Tissue Sarcomas of the Extremities with 18F-3'-Fluoro-3'-Deoxy-L-Thymidine Clin. Cancer Res., March 1, 2004; 10(5): 1685 - 1690. [Abstract] [Full Text] [PDF]

				W. Brenner, K. H. Bohuslavizki, and J. F. Eary PET Imaging of Osteosarcoma J. Nucl. Med., June 1, 2003; 44(6): 930 - 942. [Abstract] [Full Text] [PDF]

				J. P.A. Ioannidis and J. Lau 18F-FDG PET for the Diagnosis and Grading of Soft-Tissue Sarcoma: A Meta-Analysis J. Nucl. Med., May 1, 2003; 44(5): 717 - 724. [Abstract] [Full Text] [PDF]

				S F Barrington Whole body applications of positron emission tomography in oncology Imaging, September 1, 2001; 13(3): 185 - 196. [Abstract] [Full Text] [PDF]

				A. Dimitrakopoulou-Strauss, L. G. Strauss, M. Schwarzbach, C. Burger, T. Heichel, F. Willeke, G. Mechtersheimer, and T. Lehnert Dynamic PET 18F-FDG Studies in Patients with Primary and Recurrent Soft-Tissue Sarcomas: Impact on Diagnosis and Correlation with Grading J. Nucl. Med., May 1, 2001; 42(5): 713 - 720. [Abstract] [Full Text]

				H. Vesselle, R. A. Schmidt, J. M. Pugsley, M. Li, S. G. Kohlmyer, E. Vallières, and D. E. Wood Lung Cancer Proliferation Correlates with [F-18]Fluorodeoxyglucose Uptake by Positron Emission Tomography Clin. Cancer Res., October 1, 2000; 6(10): 3837 - 3844. [Abstract] [Full Text]

				A. L. Folpe, R. H. Lyles, J. T. Sprouse, E. U. Conrad III, and J. F. Eary (F-18) Fluorodeoxyglucose Positron Emission Tomography as a Predictor of Pathologic Grade and Other Prognostic Variables in Bone and Soft Tissue Sarcoma Clin. Cancer Res., April 1, 2000; 6(4): 1279 - 1287. [Abstract] [Full Text]